ZEVASKYN
|
HISTORIC achievement
In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug Administration (FDA) has approved a third treatment for this rare condition. The milestone approval of Abeona Therapeutics’ ZEVASKYN not only represents a continued commitment to innovation in RDEB care, but reinforces the growing momentum toward improved quality of life and expanded treatment choices for individuals and families affected by RDEB. ZEVASKYN is the first autologous, cell-based gene therapy for RDEB, and the first RDEB treatment designed to provide collagen VII expression at wound sites via a stably integrated copy of the COL7A1 gene.
A MODEL TO SCALE SOLUTIONS
With this FDA approval, EBRP gains continued momentum in its mission to discover treatments and a cure for EB. This milestone reinforces the validity of their scalable, sustainable Venture Philanthropy model, and, most importantly, provides treatment options and ignites hope for families around the world affected by EB.
EBRP invested in the ground-breaking work that led to ZEVASKYN at Stanford University under their Venture Philanthropy Model. The funding followed the highly competitive application and screening process overseen by EBRP’s Scientific Advisory Board (SAB), which is composed of leading scientists and physicians. EBRP was able to realize a significant return on its investment and reinvest that capital back into additional promising EB research projects.
A MODEL TO SCALE SOLUTIONS
With this FDA approval, EBRP gains continued momentum in its mission to discover treatments and a cure for EB. This milestone reinforces the validity of their scalable, sustainable Venture Philanthropy model, and, most importantly, provides treatment options and ignites hope for families around the world affected by EB.
EBRP invested in the ground-breaking work that led to ZEVASKYN at Stanford University under their Venture Philanthropy Model. The funding followed the highly competitive application and screening process overseen by EBRP’s Scientific Advisory Board (SAB), which is composed of leading scientists and physicians. EBRP was able to realize a significant return on its investment and reinvest that capital back into additional promising EB research projects.
Connect with ABEona therapeutics
Abeona’s comprehensive patient support program, Abeona Assist™, offers personalized support, including helping patients understand their insurance benefits and financial assistance options, and providing travel and logistical assistance for eligible patients. For more information on how to access ZEVASKYN, patients, caregivers, and providers may call Abeona Assist at 1-855-ABEONA-1 (1-855-223-6621) or email [email protected].
|
|
about eb research partnership
Our Mission
We're the largest global nonprofit funding research to discover treatments and cures for Epidermolysis Bullosa (EB), a group of rare and life-threatening genetic disorders that affect the body's largest organ - the skin. Children with EB lack proteins that bind the skin's two layers together, causing it to blister and shear off from even the slightest friction. To date, we've funded 160+ research projects, transforming the clinical landscape from just 2 clinical trials in EB when we were founded to 50 today.
Our Model
At EBRP, we pride ourselves on innovating to accelerate the path to a cure for EB. Through our Venture Philanthropy model, we negotiate a financial interest in the research we fund. If that research leads to a commercially successful therapy, we use our returns to fund additional EB research. In other words, your donation has the potential to grow to multiples of its original value.
We're the largest global nonprofit funding research to discover treatments and cures for Epidermolysis Bullosa (EB), a group of rare and life-threatening genetic disorders that affect the body's largest organ - the skin. Children with EB lack proteins that bind the skin's two layers together, causing it to blister and shear off from even the slightest friction. To date, we've funded 160+ research projects, transforming the clinical landscape from just 2 clinical trials in EB when we were founded to 50 today.
Our Model
At EBRP, we pride ourselves on innovating to accelerate the path to a cure for EB. Through our Venture Philanthropy model, we negotiate a financial interest in the research we fund. If that research leads to a commercially successful therapy, we use our returns to fund additional EB research. In other words, your donation has the potential to grow to multiples of its original value.
